Across TCGA pan-cancer cohorts, SYCP3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SYCP3 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher SYCP3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SYCP3 expression acts as an unfavorable survival marker.
SARC, KIRP, and UCEC are the cancer types where SYCP3 Mutation most reproducibly stratifies survival.